Report of Foreign Issuer (6-k)
02 March 2017 - 12:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of March, 2017
Commission File Number:
001-36000
XTL Biopharmaceuticals Ltd.
(Translation of registrant’s name
into English)
5 HaCharoshet St., Raanana,
4365603, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
Incorporation by Reference: This Form
6-K of XTL Biopharmaceuticals Ltd. is hereby incorporated by reference into the registration statements on Form S-8 (File No. 333-148085,
File No. 333-148754 and File No. 333-154795) and Form F-3 (File No. 333-194338).
xtl
biopharmaceuticals REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE LISTING REQUIREMENT
RAANANA,
Israel
- (March 1, 2017) – XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTLB.TA)
(“XTL”
or the “Company”), a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases, today
announced the Company has regained compliance with the listing requirements of The Nasdaq Stock Market (Nasdaq).
As previously disclosed on November 14,
2017, XTL received a letter from Nasdaq notifying the Company that it was not in compliance with Nasdaq's Listing Rule 5450(a)(1)
because the minimum bid price of the Company’s American Depositary Shares (“ADSs”) had closed below US $1.00
per share for 30 consecutive business days.
On February 28, 2017, XTL received notification
from Nasdaq that the closing price of the Company’s America Depository Share has been at $1.00 per share or greater for the
last 10 consecutive business days from February 10 through 24, 2017. Accordingly, the Company has regained compliance with Listing
Rule 5550(a)(2) and this matter is now closed.
About XTL Biopharmaceuticals Ltd.
(XTL)
XTL Biopharmaceuticals
Ltd., is a clinical-stage biotech company focused on the development of pharmaceutical products for the treatment of autoimmune
diseases. The Company’s lead drug candidate, hCDR1, is a world-class clinical asset for the treatment of autoimmune diseases
including systemic lupus erythematosus (SLE) and Sjögren’s Syndrome (SS). The few treatments currently on the market
for these diseases are not effective enough for many patients and some have significant side effects. hCDR1 has robust clinical
data in three clinical trials with 400 patients and over 200 preclinical studies with data published in more than 40 peer
reviewed scientific journals.
XTL is traded
on the Nasdaq Capital Market (NASDAQ: XTLB) and the Tel Aviv Stock Exchange (TASE: XTLB.TA). XTL shares are included in the following
indices: Tel-Aviv Biomed, Tel-Aviv MidCap, and Tel-Aviv Tech Index.
|
XTL Biopharmaceuticals Ltd.
|
|
|
5 Hacharoshet Street, Raanana, 43656, Israel
|
Page
1
|
|
Tel: +972 9 955 7080; email:
ir@xtlbio.com
|
|
For further information, please contact:
Investor Relations, XTL Biopharmaceuticals
Ltd.
Tel: +972 9 955 7080
Email:
ir@xtlbio.com
www.xtlbio.com
Stephanie Carrington
ICR, Inc.
646-277-1282
Stephanie.Carrington@icrinc.com
Media
James Heins
ICR, Inc.
203-682-8251
James.Heins@icrinc.com
Cautionary Statement
This press release may contain forward-looking
statements, about XTL’s expectations, beliefs or intentions regarding, among other things, its product development efforts,
business, financial condition, results of operations, strategies or prospects. In addition, from time to time, XTL or its representatives
have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use
of forward-looking words such as "believe," "expect," "intend," "plan," "may,"
"should" or "anticipate" or their negatives or other variations of these words or other comparable words or
by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may
be included in, but are not limited to, various filings made by XTL with the U.S. Securities and Exchange Commission, press releases
or oral statements made by or with the approval of one of XTL’s authorized executive officers. Forward-looking statements
relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking
statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that
could cause XTL’s actual results to differ materially from any future results expressed or implied by the forward-looking
statements. Many factors could cause XTL’s actual activities or results to differ materially from the activities and results
anticipated in such forward-looking statements, including, but not limited to, the factors summarized in XTL’s filings with
the SEC and in its periodic filings with the TASE. In addition, XTL operates in an industry sector where securities values are
highly volatile and may be influenced by economic and other factors beyond its control. XTL does not undertake any obligation
to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise. Please
see the risk factors associated with an investment in our ADSs or ordinary shares which are included in our Form 20-F filed with
the U.S. Securities and Exchange Commission on March 31, 2016.
|
XTL Biopharmaceuticals Ltd.
|
|
|
5 Hacharoshet Street, Raanana, 43656, Israel
|
Page
2
|
|
Tel: +972 9 955 7080; email:
ir@xtlbio.com
|
|
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
XTL BIOPHARMACEUTICALS LTD.
|
|
|
|
|
|
|
|
|
|
Date: March 1, 2017
|
By:
|
/s/ Josh Levine
|
|
|
|
Josh Levine
|
|
|
|
Chief Executive Officer
|
|
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024